Journal of International Oncology››2019,Vol. 46››Issue (8): 475-479.doi:10.3760/cma.j.issn.1673-422X.2019.08.006
Previous ArticlesNext Articles
Liu Yanfeng, Guo Hui, Sun Xiyan
Received:
2018-10-15Revised:
2019-05-10Online:
2019-08-08Published:
2019-10-31Contact:
Liu Yanfeng E-mail:350729191@qq.comLiu Yanfeng, Guo Hui, Sun Xiyan. Effects of calcium levofolinate and 5-fluorouracil combined with epirubicin on stress response and VEGF level in patients with gastric cancer[J]. Journal of International Oncology, 2019, 46(8): 475-479.
[1] Hassanalilou T, Ghavamzadeh S, Khalili L. Curcumin and gastric cancer: a review on mechanisms of action[J]. J Gastrointest Cancer, 2019, 50(2): 185-192. DOI: 10.1007/s12029-018-00186-6. [2] Graziosi L, Marino E, Donini A. Multimodal treatment of locally advanced gastric cancer: will the West meet the East[J]. Ann Surg Oncol, 2019, 26(3): 918. DOI: 10.1245/s10434-018-07141-6. [3] Li L, Kang D, Huang Z, et al. Multimodal multiphoton imaging for label-free monitoring of early gastric cancer[J]. BMC Cancer, 2019, 19(1): 295. DOI: 10.1186/s12885-019-5497-4. [4] 胡岑, 李书玲, 袁柳. 动机性访谈联合IKAP模式对晚期胃癌癌性疼痛老年患者遵医行为及生活质量的影响[J]. 中国医药导报, 2018, 15(10): 177-181. DOI: CNKI:SUN:YYCY.0.2018-10-045. [5] Hu SB, Liu CH, Wang X, et al. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer[J]. World J Surg Oncol, 2019, 17(1): 3. DOI: 10.1186/s12957-018-1534-z. [6] Wen F, Zheng H, Wu Y, et al. Cost-effectiveness analysis of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in patients with advanced gastric adenocarcinoma[J]. Sci Rep, 2016, 6: 36060. DOI: 10.1038/srep36060. [7] Kautio AL, Haanpää M, Kautiainen H, et al. Oxaliplatin scale and National Cancer lnstituteCommon Toxicitv Criteria in the assessment of chemotherapy-indnced peripheral neuropathy[J]. Anticancer Res, 2011, 31(10): 3493-3496. [8] Tanahashi T, Yoshida K, Yamaguchi K. Current status and future perspective of the chemotherapy for gastric cancer[J]. Nippon Shokakibyo Gakkai zasshi, 2018, 115(6): 500-506. DOI: 10.11405/nisshoshi.115.500. [9] Brenkman HJF, van Putten M, Visser E, et al. Timing of postoperative chemotherapy in patients undergoing perioperative chemotherapy and gastrectomy for gastric cancer[J]. Surg Oncol, 2018, 27(3): 421-427. DOI: 10.1016/j.suronc.2018.05.026. [10] Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)[J]. Gastric Cancer, 2019, 22(3): 527-535. DOI: 10.1007/s10120-018-0891-1. [11] 蔡习强, 张翠, 尹芳. 胃癌SGC7901表柔比星耐药细胞亚系的建立与耐药机制研究[J]. 现代生物医学进展, 2012, 12(14): 2658-2662. [12] Felipe AV, Oliveira J, Moraes AA, et al. Reversal of multidrug resistance in an epirubicin-resistant gastric cancer cell subline[J]. Asian Pac J Cancer Prev, 2018, 19(5): 1237-1242. DOI: 10.22034/APJCP.2018.19.5.1237. [13] Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer[J]. Cancer, 1993, 72(1): 37-41. [14] 钟锡明, 范钰, 经小珍, 等. 奥沙利铂联合亚叶酸钙和5-氟尿嘧啶治疗晚期胃癌31例分析[J]. 中国误诊学杂志, 2009, 9(1): 192-193. [15] 娄光学. 左亚叶酸钙联合5-氟尿嘧啶、奥沙利铂治疗晚期或复发胃、结直肠癌Ⅱ期的临床研究[J]. 中外医学研究, 2018, 16(1): 163-165. DOI: 10.14033/j.cnki.cfmr.2018.1.082. [16] 方瑜, 王琳, 李桂梅, 等. c-Met、VEGF、EGFR和HER-2在AFP阳性胃癌中的表达研究[J]. 中国癌症杂志, 2016, 26(8): 662-669. DOI: 10.19401/j.cnki.1007-3639.2016.08.004. [17] 黄艳芳. 紫杉醇联合5-氟尿嘧啶和亚叶酸钙方案一线治疗晚期胃癌的临床研究[D]. 福州: 福建医科大学, 2016. [18] Nguyen HG, Conn CS, Kye Y, et al. Development of a stress response therapy targeting aggressive prostate cancer[J]. Sci Transl Med, 2018, 10(439). pii: eaar2036. DOI: 10.1126/scitranslmed.aar2036. [19] Koh MJ, Jeung HC, Namkoong K, et al. Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer[J]. J Psychosom Res, 2014, 77(1): 76-80. DOI: 10.1016/j.jpsychores.2014.04.008. |
[1] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Wang Kun, Zhou Zhongxin, Zang Qiwei.Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection[J]. Journal of International Oncology, 2024, 51(4): 198-203. |
[4] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[5] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[6] | Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 89-94. |
[7] | Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[8] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[9] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[10] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[11] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[12] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[13] | Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[14] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[15] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||